Profile data is unavailable for this security.
About the company
Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The Company operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.
- Revenue in EUR (TTM)--
- Net income in EUR--
- Incorporated1997
- Employees86.00
- LocationMedigene AGLochhamer Strasse 11PLANEGG 82152GermanyDEU
- Phone+49 892000330
- Fax+49 892 000332920
- Websitehttps://www.medigene.de/
Holder | Shares | % Held |
---|---|---|
QVT Financial LPas of 11 Jan 2023 | 770.24k | 2.61% |
Deutsche Bank AG (Private Banking Germany)as of 30 Apr 2024 | 190.00k | 0.65% |
Dimensional Fund Advisors LPas of 31 Jan 2024 | 164.08k | 0.56% |
Santander Towarzystwo Funduszy Inwestycyjnych SAas of 30 Jun 2020 | 22.11k | 0.08% |
Dimensional Fund Advisors Ltd.as of 29 Feb 2024 | 4.77k | 0.02% |